http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101753561-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-0402 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-7275 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-4839 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-0402 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-00 |
| filingDate | 2015-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101753561-B1 |
| titleOfInvention | Model for prediction of QT prolongation by drugs |
| abstract | The present invention relates to a pharmacokinetic / pharmacodynamic model for the evaluation of drug-induced QT prolongation syndrome in the development of a new drug, and has been used as a limitation of the pharmacokinetic / pharmacodynamic model for predicting the QT prolongation syndrome, Induced QT prolongation syndrome by eliminating what could not distinguish the QTc interval change caused by the drug-induced QT prolongation syndrome. Therefore, the pharmacokinetic / pharmacodynamic model for the prediction of QT syndrome according to the present invention is expected to more accurately predict the risk of drug-induced arrhythmia in the development of new drugs, thereby enhancing the stability of the drug. |
| priorityDate | 2015-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 55.